We are live on ! Find out more
GCVRZ

Sanofi Contingent Value Rights

Delisted

GCVRZ was delisted on the 3rd of March, 2020.

105 hedge funds and large institutions have $57.4M invested in Sanofi Contingent Value Rights in 2017 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 15 increasing their positions, 15 reducing their positions, and 15 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $54.3M → $57.4M (+$3.12M)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

0% more repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 15

5% less funds holding

Funds holding: 111105 (-6)

33% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 15

Holders
105
Holders Change
-6
Holders Change %
-5.41%
% of All Funds
2.38%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
10
Increased
15
Reduced
15
Closed
15
Calls
$591K
Puts
Net Calls
+$591K
Net Calls Change
+$591K

GCVRZ Hedge Fund Activity: Q4 2017 in Review

105 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Sanofi Contingent Value Rights (GCVRZ) for Q4 2017, worth a combined $57.4M — up 5.8% from $54.3M a quarter earlier.

Sellers outnumbered buyers: 15 funds closed out of GCVRZ and 10 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 15 added.

The largest buyer was Stonehill Capital Management, adding an estimated $1.37M. The largest seller was TFG Asset Management, exiting entirely with an estimated $961K sold.

  • 105 institutional investors held Sanofi Contingent Value Rights (GCVRZ) as of Q4 2017, down from 111 in Q3 2017.
  • Funds reported $57.4M of Sanofi Contingent Value Rights stock for Q4 2017, up 5.8% quarter-over-quarter.
  • 10 funds opened new Sanofi Contingent Value Rights positions in Q4 2017 and 15 closed out, a net change of -5 holders.
  • The largest Sanofi Contingent Value Rights buyer in Q4 2017 was Stonehill Capital Management, an estimated $1.37M added.
  • The largest Sanofi Contingent Value Rights seller in Q4 2017 was TFG Asset Management, an estimated $961K sold.

Based on aggregated 13F filings for Q4 2017.